Get the Stockscreener App
3.52
0.85%
-0.03
After Hours:
3.60
0.08
+2.27%
Mannkind Corp stock is traded at $3.52, with a volume of 9.53M.
It is down -0.85% in the last 24 hours and up +34.87% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$3.55
Open:
$3.56
24h Volume:
9.53M
Relative Volume:
1.54
Market Cap:
$1.09B
Revenue:
$348.97M
Net Income/Loss:
$5.86M
P/E Ratio:
209.52
EPS:
0.0168
Net Cash Flow:
$13.69M
1W Performance:
+23.94%
1M Performance:
+34.87%
6M Performance:
-37.48%
1Y Performance:
-23.97%
1-Day Range:
$3.40
$3.68
1-Week Range:
$2.78
$4.29
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.52 | 1.09B | 348.97M | 5.86M | 13.69M | 0.0168 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MNKD Technical Analysis & Stock Price Forecast - Intellectia AI
MNKD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Q1 2026 MannKind Corp Earnings Call Transcript - GuruFocus
MNKD stock records biggest single-day gains in over 5 years, breaches a key technical milestone – what’s driving this rally? - MSN
Wall Street Zen Downgrades MannKind (NASDAQ:MNKD) to Sell - MarketBeat
MannKind (MNKD) CEO clarifies 100,000-share Form 4 error in amendment - Stock Titan
MNKD Maintained by RBC Capital -- Price Target Raised to $4.75 - GuruFocus
MNKD Maintains Overweight Rating -- Price Target Raised to $10.0 - GuruFocus
MannKind Corporation (NASDAQ:MNKD) Q1 2026 Earnings Call Transcript - Insider Monkey
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead By Investing.com - Investing.com Canada
MannKind (NASDAQ:MNKD) Announces Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
MannKind Q1 Earnings Call Highlights - Yahoo Finance
MannKind Corporation Q1 2026 Earnings Call Summary - Yahoo Finance
MannKind Q1 2026 slides: revenue up 15%, three catalysts ahead - Investing.com
Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call transcript: MannKind Q1 2026 sees revenue growth, stock surges - Investing.com
MannKind Corp (NASDAQ:MNKD) Q1 2026 Revenue Miss and Wider EPS Loss Overshadow Strong Pipeline Progress - ChartMill
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
MannKind: Q1 Earnings Snapshot - Barchart.com
Revenue growth but net loss for MannKind (NASDAQ: MNKD) in Q1 2026 - Stock Titan
MannKind heads into two FDA decisions after posting $90.2M in Q1 - Stock Titan
MannKind (NASDAQ: MNKD) Q1 2026 revenue rises 15% as Furoscix ramps - Stock Titan
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update - ChartMill
MNKD Stock Records Biggest Single-Day Gains In Over 5 Years, Breaches A Key Technical Milestone – What’s Driving This Rally? - Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Keep an eye on the top gainers and losers in Wednesday's session. - ChartMill
Why is MannKind stock surging today? By Investing.com - Investing.com Canada
Why is MannKind stock surging today? - Investing.com
MannKind stock surges on United Therapeutics partnership deal - Investing.com
Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday - Benzinga
Wednesday's session: gap up and gap down stocks - ChartMill
MannKind advances inhaled ralinepag program for lung diseases - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
MannKind develops inhaled ralinepag formulation for United Therapeutics By Investing.com - Investing.com South Africa
MannKind develops inhaled ralinepag formulation for United Therapeutics - Investing.com
At least five PDUFA dates on FDA’s May docket - biocentury.com
MNKD Technical Analysis | Trend, Signals & Chart Patterns | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Is MannKind Corporation (MNKD) The Best Fundamentally Strong Penny Stock to Invest In Now? - Insider Monkey
MannKind settles $36.3M convertible notes with cash, shares - Investing.com
5 Best Fundamentally Strong Penny Stocks to Invest In Now - Insider Monkey
MannKind (MNKD) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
MannKind sets May 6 earnings release, 4:30 p.m. webcast - Stock Titan
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026 - ChartMill
MNKD Maintained by Wells Fargo -- Price Target Raised to $8.00 - GuruFocus
MannKind (NASDAQ:MNKD) Trading Up 5.5% Following Analyst Upgrade - MarketBeat
Wells Fargo & Company Boosts MannKind (NASDAQ:MNKD) Price Target to $8.00 - MarketBeat
HC Wainwright Estimates MannKind's Q1 Earnings (NASDAQ:MNKD) - MarketBeat
MannKind (MNKD) CFO has shares withheld for RSU tax obligations - Stock Titan
FY2027 EPS Estimates for MannKind Reduced by HC Wainwright - MarketBeat
How The MannKind (MNKD) Story Is Shifting With Tyvaso DPI And Soft Mist Uncertainty - Yahoo Finance
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tross Stuart A | Chief People & Workpl Officer |
Jan 08 '26 |
Sale |
6.33 |
47,006 |
297,548 |
985,007 |
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):